source
- Novartis' DM1 drug del-desiran misses primary endpoint in Phase 3 HARBOR trialNovartis announced that its experimental therapy del-desiran did not improve muscle function in a pivotal Phase 3 study for myotonic dystrophy type 1 (DM1). The trial, called HARBOR, evaluated the…
- Hospitals pursue deals to ensure survival as Trump’s Medicaid cuts loomRural health systems are seeking partnership to survive, fueling a debate over competition and the rising cost of medical care.STAT · 1h ago↗ source